drugset / Trial / NCT04347005

The Study is Designed to Evaluate Single Ascending Doses of AR882 in Healthy Adult Males

NCT04347005

Phase 1 Completed 64 enrolled Arthrosi Therapeutics
RandomizedParallel-groupTriple-blindTreatment

Summary

A randomized, double-blind, placebo-controlled, single ascending dose study of AR882 in healthy adult males.

Timeline

Start
2019-01-22
Primary completion
2019-07-31
Completion
2019-07-31

Drugs

EvaluationDrugModalityDoseRoute
Subject AR882 Unknown
Subject Allopurinol Small molecule
Subject Febuxostat Small molecule

Indications

No indication recorded.